IDEAS home Printed from https://ideas.repec.org/a/bhx/ijhmnp/v6y2024i2p44-51id1705.html
   My bibliography  Save this article

Effectiveness of Ophtascan Screening in Lubumbashi. Pilot Study on Screening for Cancer and Type 2 Diabetes

Author

Listed:
  • Dsir Kamba Banza
  • Robert Mbuli Lukamba
  • Simon Henry Opio-Emuna
  • Cilundika Phillippe
  • Amani Chuma
  • Jean-Paul Mande Ngoy
  • Dophra Nkulu Ngoy
  • Albert Tambwe Nkoy Mwembo
  • Oscar Numbi Luboya

Abstract

Purpose: Screening and early treatment are the best strategy for controlling cancer and type 2 diabetes (T2DM). Based on artificial intelligence, new software Ophtascan allows the early detection of the following cancers: cervix, endometrium, breast, prostate, lung as well as type 2 diabetes, from the image of the eyes. The objectives of this study were to test the reliability of the test in the detection of type 2 diabetes and to present the prevalence of oncological pathologies detected. Methodology: screening was carried out in two stages: a technical test of the program and mass screening at the University Clinics of Lubumbashi and the Sendwe Hospital of Lubumbashi among volunteers from April 2023 to July 2023. Findings: Of the 98 volunteers screened including 32 men and 66 women, the risk of the following cancers was detected by Ophtascan: in men, 12.5%, 28% and 6% respectively for the prostate, lung (pre-cancer) and lung while in women we had 1.5%, 6%, 3%, 4.5% and 3% respectively for cervix (pre-cancer), cervical cancer, endometrial, breast (pre- cancer) and breast. This cancer screening trial was not accompanied by clinical confirmation of detected diseases due high cost and practical problems. T2DM trial was accompanied by lab blood test for confirmation of results. Proved sensitiviy of Ophtascan for T2DM achieved 91% within blind clinical trial and 100% within technical trial, and 72% of screened people did not suspect they had this disease, detected by Ophtascan. Unique Contribution to theory, Policy and Practice: Ophtascan is feasible in our environment and seems to have high reliability for the detection of type 2 diabetes as screening tool. Ophtascan certainly detected most of the targeted cancers, but the low number of cases does not allow solid conclusions to be drawn. The difficulty of validation for all types of cancer mentioned above due to its high cost for patients, we propose to carry out a new pilot research project which will focus on cervical cancer, for which early treatment is possible at a low cost in our environment.

Suggested Citation

  • Dsir Kamba Banza & Robert Mbuli Lukamba & Simon Henry Opio-Emuna & Cilundika Phillippe & Amani Chuma & Jean-Paul Mande Ngoy & Dophra Nkulu Ngoy & Albert Tambwe Nkoy Mwembo & Oscar Numbi Luboya, 2024. "Effectiveness of Ophtascan Screening in Lubumbashi. Pilot Study on Screening for Cancer and Type 2 Diabetes," International Journal of Health, Medicine and Nursing Practice, CARI Journals Limited, vol. 6(2), pages 44-51.
  • Handle: RePEc:bhx:ijhmnp:v:6:y:2024:i:2:p:44-51:id:1705
    as

    Download full text from publisher

    File URL: https://carijournals.org/journals/index.php/IJHMNP/article/view/1705/2079
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bhx:ijhmnp:v:6:y:2024:i:2:p:44-51:id:1705. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Chief Editor (email available below). General contact details of provider: https://www.carijournals.org/journals/index.php/IJHMNP/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.